Citadel Advisors’s Calithera Biosciences, Inc CALA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,475
| Closed | -$64K | – | 15335 |
|
|
2021
Q3 | $64K | Buy |
1,475
+475
| +48% | +$20.5K | ﹤0.01% | 13234 |
|
|
2021
Q2 | $42K | Sell |
1,000
-405
| -29% | -$17.8K | ﹤0.01% | 13402 |
|
|
2021
Q1 | $68K | Sell |
1,405
-2,410
| -63% | -$140K | ﹤0.01% | 12758 |
|
|
2020
Q4 | $375K | Buy |
3,815
+3,285
| +620% | +$288K | ﹤0.01% | 8681 |
|
|
2020
Q3 | $37K | Buy |
+530
| New | +$46.2K | ﹤0.01% | 9703 |
|
|
2020
Q1 | – | Sell |
-890
| Closed | -$102K | – | 10437 |
|
|
2019
Q4 | $102K | Buy |
+890
| New | +$66.9K | ﹤0.01% | 8541 |
|
|
2018
Q4 | – | Sell |
-845
| Closed | -$89K | – | 10009 |
|
|
2018
Q3 | $89K | Sell |
845
-890
| -51% | -$84.7K | ﹤0.01% | 8622 |
|
|
2018
Q2 | $174K | Buy |
1,735
+650
| +60% | +$73.6K | ﹤0.01% | 7992 |
|
|
2018
Q1 | $137K | Buy |
+1,085
| New | +$169K | ﹤0.01% | 7592 |
|
|
2017
Q3 | – | Sell |
-1,390
| Closed | -$413K | – | 8242 |
|
|
2017
Q2 | $413K | Buy |
1,390
+355
| +34% | +$94.9K | ﹤0.01% | 5399 |
|
|
2017
Q1 | $239K | Buy |
+1,035
| New | +$179K | ﹤0.01% | 6239 |
|
|
2016
Q1 | – | Sell |
-490
| Closed | -$75K | – | 8369 |
|
|
2015
Q4 | $75K | Hold |
490
| – | – | ﹤0.01% | 6971 |
|
|
2015
Q3 | $53K | Buy |
+490
| New | +$63.5K | ﹤0.01% | 7543 |
|
Other funds holding CALA
Citadel Advisors's CALA Position: Q1 2023 in Review
Citadel Advisors sold out of Calithera Biosciences, Inc (CALA) in Q1 2023, closing a stake of 199,269 shares — an estimated $650K sold.
Citadel Advisors first reported a position in CALA in Q3 2015 and held it in 24 quarters. The position peaked at $8.48M in Q2 2017. 2 funds tracked by Wall St. Rank hold CALA as of Q1 2023.
- Citadel Advisors reported no remaining Calithera Biosciences, Inc position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 199,269 Calithera Biosciences, Inc shares in Q1 2023, an estimated $650K.
- Citadel Advisors first reported a position in Calithera Biosciences, Inc in Q3 2015 and held it in 24 quarters.
- Citadel Advisors's Calithera Biosciences, Inc position peaked at $8.48M in Q2 2017.
- 2 funds tracked by Wall St. Rank held Calithera Biosciences, Inc as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.